These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 21904579)

  • 1. The role of the c-Met pathway in lung cancer and the potential for targeted therapy.
    Sattler M; Reddy MM; Hasina R; Gangadhar T; Salgia R
    Ther Adv Med Oncol; 2011 Jul; 3(4):171-84. PubMed ID: 21904579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer.
    Miranda O; Farooqui M; Siegfried JM
    Cancers (Basel); 2018 Aug; 10(9):. PubMed ID: 30134579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of HGF/MET axis in resistance of lung cancer to contemporary management.
    Raghav KP; Gonzalez-Angulo AM; Blumenschein GR
    Transl Lung Cancer Res; 2012 Sep; 1(3):179-93. PubMed ID: 25806180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. c-MET as a potential therapeutic target and biomarker in cancer.
    Sierra JR; Tsao MS
    Ther Adv Med Oncol; 2011 Nov; 3(1 Suppl):S21-35. PubMed ID: 22128285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors.
    Smyth EC; Sclafani F; Cunningham D
    Onco Targets Ther; 2014; 7():1001-14. PubMed ID: 24959087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MET inhibitors in combination with other therapies in non-small cell lung cancer.
    Padda S; Neal JW; Wakelee HA
    Transl Lung Cancer Res; 2012 Dec; 1(4):238-53. PubMed ID: 25806189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody.
    Kou J; Musich PR; Staal B; Kang L; Qin Y; Yao ZQ; Zhang B; Wu W; Tam A; Huang A; Hao HX; Vande Woude GF; Xie Q
    J Transl Med; 2018 Sep; 16(1):253. PubMed ID: 30208970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the MET receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinib.
    Agwa ES; Ma PC
    Cancer Manag Res; 2014; 6():397-404. PubMed ID: 25328417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Listeria protein internalin B mimics hepatocyte growth factor-induced receptor trafficking.
    Li N; Xiang GS; Dokainish H; Ireton K; Elferink LA
    Traffic; 2005 Jun; 6(6):459-73. PubMed ID: 15882443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocyte growth factor/MET in cancer progression and biomarker discovery.
    Matsumoto K; Umitsu M; De Silva DM; Roy A; Bottaro DP
    Cancer Sci; 2017 Mar; 108(3):296-307. PubMed ID: 28064454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The MET axis as a therapeutic target.
    Sattler M; Salgia R
    Update Cancer Ther; 2009 Apr; 3(3):109-118. PubMed ID: 20368753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
    Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
    Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands.
    Yano S; Takeuchi S; Nakagawa T; Yamada T
    Cancer Sci; 2012 Jul; 103(7):1189-94. PubMed ID: 22435662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increase in hepatocyte growth factor receptor tyrosine kinase activity in renal carcinoma cells is associated with increased motility partly through phosphoinositide 3-kinase activation.
    Nakamura T; Kanda S; Yamamoto K; Kohno T; Maeda K; Matsuyama T; Kanetake H
    Oncogene; 2001 Nov; 20(52):7610-23. PubMed ID: 11753639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy.
    Sattler M; Salgia R
    Curr Oncol Rep; 2007 Mar; 9(2):102-8. PubMed ID: 17288874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition.
    Maulik G; Shrikhande A; Kijima T; Ma PC; Morrison PT; Salgia R
    Cytokine Growth Factor Rev; 2002 Feb; 13(1):41-59. PubMed ID: 11750879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer.
    Yamada T; Takeuchi S; Kita K; Bando H; Nakamura T; Matsumoto K; Yano S
    J Thorac Oncol; 2012 Feb; 7(2):272-80. PubMed ID: 22089117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
    Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
    Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.